Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
STEMSOFT Announces Release of New BMT Clinic Software Solution
STEMSOFT™ Software Inc. announced the release of a new BMT cellular therapy transplant software solution, STEMSOFT CLINIC. This new system efficiently manages all patient and donor information in one location complete with an available BMT registry submission and retrieval process for all available forms using the CIBMTR AGNIS system. [STEMSOFT™ Software Inc.]
ATL1102 for Stem Cell Mobilization Trial Commencement
Antisense Therapeutics advised that it has commenced dosing in its Phase I Stem Cell Mobilization Human Proof of Concept trial of ATL1102, the company’s second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor). [PR Newswire Association LLC]